Metrics as of 10/16/2026, 07:17 PM (Berlin time), refresh in progress.
Avalo Therapeutics Stock
Avalo Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Garry A. Neil
- Employees
- 33
- Market cap
- $610 M
- IPO
- 14/10/2015
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key…
Avalo Therapeutics stock: price history
1D
-4.9%
1W
-16.3%
1M
-31.1%
6M
-20.9%
YTD
-37.1%
1Y
-18.4%
2Y
+11.0%
5Y
-99.8%
10Y
-99.9%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~36% weaker price swings than usual
Ask the agents about Avalo Therapeutics
Analyst assessment of Avalo Therapeutics
PRICE TARGET LOW
US$30.00
CONSENSUS
US$44.71
MEDIAN
US$45.00
PRICE TARGET HIGH
US$60.00
0
STRONG BUY
8
BUY
1
HOLD
1
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 07/08/2026
Avalo Therapeutics stock metrics
P/E
-2.4
P/B
1.11
EV/EBITDA
-5.25
RETURN ON EQUITY
-8.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
89.6%
FLOAT SHARES
48,057,253
AVG. DAILY VOLUME (30D)
1,086,859
Insider transactions (SEC)
Sullivan Christopher Ryan
Sullivan Christopher Ryan
Sullivan Christopher Ryan
Sullivan Christopher Ryan
Doyle Mittie
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Avalo Therapeutics stock
What does Avalo Therapeutics do?
Avalo Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Garry A. Neil, the company employs around 33 people.
The IPO was on 14/10/2015; the stock trades on NASDAQ under the ticker AVTX.
What do analysts say about Avalo Therapeutics stock?
10 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$44.71, ranging from US$30.00 to US$60.00, with a median of US$45.00.
This is an external assessment, not a statement by Market Jury.
When does Avalo Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -36% stronger than usual.
Does Avalo Therapeutics pay a dividend?
No, Avalo Therapeutics currently does not pay a dividend.
Which stocks are comparable to Avalo Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Avalo Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Avalo Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.